Scott D Beattie
Overview
Explore the profile of Scott D Beattie including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
492
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hoffman R, Beattie S, Camp J, Fuhs J
Ther Innov Regul Sci
. 2023 Apr;
57(4):689-701.
PMID: 37014601
The United States Food and Drug Administration (FDA) implemented "the Program" in 2012 to promote greater transparency and increased communication between the FDA and applicants of New Molecular Entity (NME)...
2.
Camp J, Fuhs J, Beattie S, Asay R, Hoffman R
Ther Innov Regul Sci
. 2021 Jan;
55(3):568-582.
PMID: 33492633
The United States Food and Drug Administration (FDA) implemented the PDUFA V New Molecular Entity (NME) Program (the Program) in 2012 to promote greater transparency and increased communication between the...
3.
Peterfy C, DiCarlo J, Emery P, Genovese M, Keystone E, Taylor P, et al.
J Rheumatol
. 2019 Jan;
46(8):887-895.
PMID: 30647190
Objective: Magnetic resonance imaging (MRI) was used in a phase IIb study of baricitinib in patients with RA to support dose selection for the phase III program. Methods: Three hundred...
4.
Keystone E, Genovese M, Schlichting D, de la Torre I, Beattie S, Rooney T, et al.
J Rheumatol
. 2017 Aug;
45(1):14-21.
PMID: 28811354
Objective: To assess the safety and efficacy of baricitinib in patients with rheumatoid arthritis (RA) up to 128 weeks in a phase IIb study (NCT01185353). Methods: After a 24-week blinded...
5.
Kremer J, Genovese M, Keystone E, Taylor P, Zuckerman S, Ruotolo G, et al.
Arthritis Rheumatol
. 2016 Dec;
69(5):943-952.
PMID: 28029752
Objective: To assess the effects of baricitinib on lipid profiles in patients with moderate-to-severe rheumatoid arthritis. Methods: Treatment with once-daily doses of baricitinib (1, 2, 4, or 8 mg) or...
6.
Genovese M, Kremer J, Zamani O, Ludivico C, Krogulec M, Xie L, et al.
N Engl J Med
. 2016 Mar;
374(13):1243-52.
PMID: 27028914
Background: In phase 2 studies, baricitinib, an oral Janus kinase 1 and 2 inhibitor, reduced disease activity in patients with rheumatoid arthritis who had not previously received treatment with biologic...
7.
Keystone E, Taylor P, Drescher E, Schlichting D, Beattie S, Berclaz P, et al.
Ann Rheum Dis
. 2014 Nov;
74(2):333-40.
PMID: 25431052
Objectives: To investigate baricitinib (LY3009104, formerly INCB028050), a novel, oral inhibitor of JAK1/JAK2 in patients with moderate to severe rheumatoid arthritis (RA) despite treatment with methotrexate. Methods: In this phase...
8.
Milicevic Z, Raz I, Beattie S, Campaigne B, Sarwat S, Gromniak E, et al.
Diabetes Care
. 2008 Feb;
31 Suppl 2:S155-60.
PMID: 18227478
Atherosclerotic vascular disease is more common in diabetic than in nondiabetic individuals. Diabetic macrovascular disease also has a more severe course with greater prevalence of multiple-vessel coronary artery disease and...
9.
Gale E, Beattie S, Hu J, Koivisto V, Tan M
Diabetes Care
. 2007 Sep;
30(12):2989-92.
PMID: 17804681
Objective: We assessed the effect upon A1C of recruitment to a clinical trial in patients with diabetes who had been screened and interviewed to determine eligibility but whose therapy was...
10.
Milicevic Z, Raz I, Strojek K, Skrha J, Tan M, Wyatt J, et al.
J Diabetes Complications
. 2005 Mar;
19(2):80-7.
PMID: 15745837
Objective: Cardiovascular (CV) disease is the major cause of death in patients with diabetes. Up to 40% of patients with Type 2 diabetes mellitus (T2DM) who survive an initial myocardial...